Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Etrumadenant by Arcus Biosciences for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
Etrumadenant by Arcus Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Etrumadenant by Arcus Biosciences for Breast Cancer: Likelihood of Approval
Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase I for Breast Cancer. According to GlobalData, Phase...
Etrumadenant by Arcus Biosciences for Renal Cell Carcinoma: Likelihood of Approval
Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...
Etrumadenant by Arcus Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval
Etrumadenant is under clinical development by Arcus Biosciences and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData,...
Domvanalimab by Arcus Biosciences for Esophageal Cancer: Likelihood of Approval
Domvanalimab is under clinical development by Arcus Biosciences and currently in Phase III for Esophageal Cancer. According to GlobalData, Phase...
Domvanalimab by Arcus Biosciences for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Domvanalimab is under clinical development by Arcus Biosciences and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According...
Domvanalimab by Arcus Biosciences for Gastric Cancer: Likelihood of Approval
Domvanalimab is under clinical development by Arcus Biosciences and currently in Phase III for Gastric Cancer. According to GlobalData, Phase...
AB-598 by Arcus Biosciences for Gastric Cancer: Likelihood of Approval
AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
AB-598 by Arcus Biosciences for Esophageal Cancer: Likelihood of Approval
AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...
AB-598 by Arcus Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Non-Small Cell Lung Cancer. According to...
AB-598 by Arcus Biosciences for Renal Cell Carcinoma: Likelihood of Approval
AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...
AB-598 by Arcus Biosciences for Bladder Cancer: Likelihood of Approval
AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...
Quemliclustat by Arcus Biosciences for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Quemliclustat is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
AB-598 by Arcus Biosciences for Cervical Cancer: Likelihood of Approval
AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...
AB-598 by Arcus Biosciences for Ovarian Cancer: Likelihood of Approval
AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Zimberelimab by Arcus Biosciences for Gastric Cancer: Likelihood of Approval
Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
AB-801 by Arcus Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
AB-801 is under clinical development by Arcus Biosciences and currently in Phase I for Non-Small Cell Lung Cancer. According to...
AB-521 by Arcus Biosciences for Metastatic Renal Cell Carcinoma: Likelihood of Approval
AB-521 is under clinical development by Arcus Biosciences and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...
AB-598 by Arcus Biosciences for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
AB-598 is under clinical development by Arcus Biosciences and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...